Concord Healthcare Announces Completion of China’s First Proton Therapy for Choroidal Malignant Melanoma
BEIJING, July 15, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary...
LABCONNECT APPOINTS MITCHELL BLUMENFELD AS CHIEF FINANCIAL OFFICER
JOHNSON CITY, Tenn., July 15, 2025 /PRNewswire/ -- LabConnect is pleased to announce the appointment of Mitch Blumenfeld as its Chief Financial Officer, effective August 4, 2025. Mitch joins LabConnect with proven experience as Chief Financial Officer for high-growth companies in multiple industries including pharmaceutical services, wholesale pharmaceutical distribution, and diversified manufacturing...
Health In Tech to Announce Second Quarter 2025 Financial Results on July 21, 2025
STUART, Fla., July 15, 2025 /PRNewswire/ -- Health In Tech (NASDAQ: HIT), an Insurtech platform company backed by third-party AI technology, today announced that it will release financial results for the quarter ended June 30, 2025, following the close of market on Monday, July 21, 2025. Health In Tech will host a conference...
Zepp Health Corporation to Report Second Quarter 2025 Financial Results on August 3, 2025
Earnings Call Scheduled for 9:30 p.m. ET on August 3, 2025 MILPITAS, Calif., July 14, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its second quarter 2025 unaudited financial results on Sunday, August 3, 2025. Management will hold a conference call at 9:30...
Waters and BD’s Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted...
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- The Series B round saw strong participation from both existing and new...
Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot
Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU, Finland, July 14, 2025 /PRNewswire/ -- Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generation sequencing announces the results of a clinical pilot study published in Scientific Reports,...
MGI Tech Won Green World Award for Sustainable Contribution to Thai Mangroves Conservation Efforts
AUCKERLAND, New Zealand, July 14, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to announce that it has been awarded the Green World Champion in the Environmental Improvement: Conservation & Wildlife Projects sector of...
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy in relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive type of blood...
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a...
